A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD

Summary Background Fluticasone furoate (FF)/vilanterol (VI) is a novel once-daily inhaled corticosteroid/long-acting β2 -agonist combination therapy for COPD. We aimed to assess the efficacy and safety of two strengths of FF/VI (100/25 μg; 50/25 μg) vs. individual components (FF 100 μg, VI 25 μg) an...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Respiratory medicine 2013-04, Vol.107 (4), p.560-569
Hauptverfasser:	Kerwin, Edward M, Scott-Wilson, Catherine, Sanford, Lisa, Rennard, Stephen, Agusti, Alvar, Barnes, Neil, Crim, Courtney
Format:	Artikel
Sprache:	eng
Schlagworte:	Adrenergic beta-2 Receptor Agonists - adverse effects Adrenergic beta-2 Receptor Agonists - therapeutic use Aged Androstadienes - administration & dosage Androstadienes - adverse effects Androstadienes - therapeutic use Antibiotics Benzyl Alcohols - adverse effects Benzyl Alcohols - therapeutic use Bronchodilator Agents - administration & dosage Bronchodilator Agents - adverse effects Bronchodilator Agents - therapeutic use Chlorobenzenes - adverse effects Chlorobenzenes - therapeutic use Chronic obstructive pulmonary disease COPD Dose-range Dose-Response Relationship, Drug Double-Blind Method Drug Combinations Drug therapy Female Forced Expiratory Volume - drug effects Glucocorticoids - administration & dosage Glucocorticoids - adverse effects Glucocorticoids - therapeutic use Humans ICS Infections LABA Lung function Male Middle Aged Mortality Once-daily Oxygen therapy Pulmonary Disease, Chronic Obstructive - drug therapy Pulmonary Disease, Chronic Obstructive - physiopathology Pulmonary/Respiratory Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!